Episode Details

Back to Episodes
Pharmaceutical Executive Daily: Novo Nordisk Enters Rebrand

Pharmaceutical Executive Daily: Novo Nordisk Enters Rebrand

Published 2 months ago
Description
Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in obesity and diabetes care, and Wendy Short Bartie of Bristol Myers Squibb makes the case for reputation as a strategic currency.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us